摘要
目的观察后房型有晶状体眼人工晶状体（PCPIOL）矫治高度近视眼的长期安全性和有效性。方法高度近视眼患者41例（66只眼），等效球镜度数（SE）（－15．12±3．93）D，植入PCPIOL。术后随访3年，观察手术前后的视力、屈光状态、眼压、角膜、前房、瞳孔、PCPIOL和晶状体、眼底情况，并进行比较。结果与术前比较，术后3、6个月、1、2、3年的裸眼视力（UCVA）、最佳矫正视力（BCVA）和SE显著改善。术后3年时，UCVA≥0．5有86％，≥0．8有43％；BCVA未见下降，11％比术前提高1行，68％比术前提高≥2行；96％眼的实际屈光度数稳定在预期的±1．00D，57％稳定在预期的±0．50D。术后1、2、3年的角膜内皮细胞累积丢失率分别为9．26％、12．84％、18．54％。除了1只眼黄斑出血外，未见其他并发症发生。结论PCPIOL矫治高度近视术后3年内安全、有效。
Objective To investigate long-term efficacy and safety of a posterior chamber phakic intraocular lens （PCPIOL） implantation for high myopia. Methods A consecutive group of 66 eyes in 41 patients with -15.12± 3.93 diopters （D） of myopia was implanted with the ICL PCPIOL （STAAR）, and was examined preoperatively and 1, 2, 3 years postoperatively. Uncorrected visual acuity （UCVA）, best corrected visual acuity （BCVA）, manifest refi＇action, intraocular pressure, and complications were evaluated. Results The im- plantation was successful in all of 66 eyes. Compared with preoperative data, UCVA, BCVA, and spherical equivalent （SE） were improved significantly. At 3-year postoperatively, UCVA in 86% eyes was 0.5 or better, in 43% was 0.8 or better; No loss of BCVA was found, 11% gained 1 line, and 68% gained 2 lines or more; SE in 96%, 57% eyes was within ：1：1.00 D, ± 0.50D of attempted, respectively. At 1-, 2-, 3-year follow-up, the corneal endothelial loss was 9.26%, 12.84%, 18.54%, respectively. No severe complications occurred expect 1 macular hemorrhage due to CNV. Conclusions At 3-year follow-up, the implantation of the PCPIOL proved to be safe and effective for the correction of myopia in phakic eyes.
出处
《中国实用眼科杂志》
CSCD
北大核心
2010年第9期1004-1006,共3页
Chinese Journal of Practical Ophthalmology
基金
“十五”国家科技攻关计划（2004BA720A16）
关键词
晶状体
人工
眼科手术
近视
Lens
Intraocular
Ophthalmologic surgical procedures
Myopia
